Quick Answer
AVENUE THERAPEUTICS, INC. reported Research And Development Expense of $1.04 million for the year ending 2025.
- AVENUE THERAPEUTICS, INC. showed a decrease of -84.4% in Research And Development Expense from 2024 to 2025.
- This data is from AVENUE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2015 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $564.0 thousand | Q2 2016: $421.0 thousand | Q3 2016: $183.0 thousand | Q1 2017: $133.0 thousand | Q2 2017: $447.0 thousand | Q3 2017: $2.00 million | Q1 2018: $9.44 million | Q2 2018: $3.75 million | Q3 2018: $1.79 million | Q1 2019: $10.24 million | Q2 2019: $6.39 million | Q3 2019: $1.71 million | Q1 2020: $697.0 thousand | Q2 2020: $1.22 million | Q3 2020: $466.0 thousand | Q1 2021: $258.0 thousand | Q2 2021: $328.0 thousand | Q3 2021: $278.0 thousand | Q1 2022: $1.81 million | Q2 2022: $151.0 thousand | Q3 2022: $194.0 thousand | Q1 2023: $1.22 million | Q2 2023: $3.03 million | Q3 2023: $907.0 thousand | Q1 2024: $2.39 million | Q2 2024: $1.36 million | Q3 2024: $2.33 million | Q1 2025: $411.0 thousand | Q2 2025: $192.0 thousand | Q3 2025: $177.0 thousand.
- Over the full 12 years of available data (2015 to 2025), AVENUE THERAPEUTICS, INC.'s Research And Development Expense has grown by 7.9%.
- Historical annual values: Fiscal year 2025: $1.04 million | Fiscal year 2024: $6.65 million | Fiscal year 2023: $6.13 million | Fiscal year 2022: $2.70 million | Fiscal year 2022: $300.0 thousand | Fiscal year 2021: $1.25 million | Fiscal year 2020: $2.87 million | Fiscal year 2019: $22.19 million | Fiscal year 2018: $17.70 million | Fiscal year 2017: $6.70 million | Fiscal year 2016: $1.33 million | Fiscal year 2015: $961.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: